Lilly’s regulatory application seeking approval of Zepbound for OSA is also under review in the EU. New Indications to Expand LLY’s Tirzepatide Label Other than Zepbound, Lilly markets ...

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Lilly’s regulatory application seeking approval of Zepbound for OSA is also under review in the EU. Other than Zepbound, Lilly markets tirzepatide as Mounjaro for type II diabetes. Mounjaro and ...

Zepbound’s approval for OSA was based on data from SURMOUNT-OSA phase III studies. Lilly’s regulatory application seeking approval of Zepbound for OSA is also under review in the EU.

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Lilly’s application to the FDA was supported by data from two phase 3 clinical trials this year. Zepbound was about five ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...